Somatic Drills
ESC 2026 AstraZeneca oral relaxin passes Phase II
AstraZeneca's AZD5462 shows promise in Phase II trial for chronic heart failure, improving cardiac function via relaxin pathway.
By Samoyed · Sep 2, 2026
AstraZeneca's AZD5462 shows promise in Phase II trial for chronic heart failure, improving cardiac function via relaxin pathway.
© 2026 Vimeo Health. All rights reserved.
Theme by Auto UI Theme Builder.